Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
19 Setembro 2023 - 9:00AM
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company
leveraging its innovative virus-like particle (VLP) platform
technology to develop vaccines against infectious diseases, with an
initial focus on life-threatening respiratory diseases and a vision
of creating pan-respiratory vaccines for older adults, today
announced that the company will participate in the Cantor
Fitzgerald Global Healthcare Conference 2023, taking place from
September 26-28, 2023 in New York City.
Cantor Fitzgerald Global Healthcare Conference
2023
- Adam Simpson, Chief Executive
Officer of Icosavax, will participate in a fireside chat in New
York City on Tuesday, September 26 at 8:45 am ET in Track 3
Interested parties can register for and access the live webcast
for this conference by visiting the “Events” section of the
Icosavax website. The webcast replay will be available after the
conclusion of the presentation.
About Icosavax
Icosavax is a biopharmaceutical company leveraging its
innovative VLP platform technology to develop vaccines against
infectious diseases, with an initial focus on life-threatening
respiratory diseases and a vision for combination and
pan-respiratory vaccines. Icosavax’s VLP platform technology is
designed to enable multivalent, particle-based display of complex
viral antigens, which it believes will induce broad, robust, and
durable protection against the specific viruses targeted.
Icosavax’s lead program is a combination vaccine candidate
targeting respiratory syncytial virus (RSV) and human
metapneumovirus (hMPV), and its pipeline includes additional
programs in influenza and severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance
the breakthrough VLP technology from the Institute for Protein
Design at the University of Washington with the goal to discover,
develop, and commercialize vaccines against infectious diseases.
Icosavax is located in Seattle.
For more information, visit www.icosavax.com.
Media Contact:Jessica Yingling,
Ph.D.,Little Dog Communications
Inc.jessica@litldog.com858.344.8091
Investor Contact:Laurence WattsGilmartin Group,
LLClaurence@gilmartinir.com619.916.7620
Icosavax (NASDAQ:ICVX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Icosavax (NASDAQ:ICVX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024